Contineum Therapeutics (NASDAQ:CTNM) Cut to Sell at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen lowered shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, October 8th. Leerink Partners assumed coverage on Contineum Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $22.00 price target on the stock. Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Monday, August 18th. Robert W. Baird dropped their price objective on shares of Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, November 24th. Finally, Leerink Partnrs raised shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.40.

Check Out Our Latest Analysis on CTNM

Contineum Therapeutics Trading Down 0.4%

NASDAQ:CTNM opened at $11.58 on Friday. The company has a market cap of $337.90 million, a P/E ratio of -5.15 and a beta of 1.25. Contineum Therapeutics has a twelve month low of $3.35 and a twelve month high of $15.25. The company’s 50-day moving average price is $11.32 and its 200-day moving average price is $8.70.

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.13. On average, analysts expect that Contineum Therapeutics will post -2.01 earnings per share for the current year.

Institutional Trading of Contineum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio acquired a new position in Contineum Therapeutics in the first quarter valued at about $27,000. Bank of America Corp DE increased its position in shares of Contineum Therapeutics by 500.0% during the third quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after acquiring an additional 6,030 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at approximately $43,000. Marex Group plc acquired a new position in shares of Contineum Therapeutics in the 2nd quarter worth approximately $45,000. Finally, Bailard Inc. purchased a new position in shares of Contineum Therapeutics during the 3rd quarter worth approximately $145,000.

Contineum Therapeutics Company Profile

(Get Free Report)

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

Further Reading